Medcast news and blog
Anthony is having frequent exacerbations of his COPD….why is his physician considering a GLP1 agonist?
Anthony is a retired engineer, who is compliant with his COPD and diabetes management but has been struggling with frequent exacerbations of his COPD.
READ ON![Clinical Opal #11 - SGLT2i-related DKA](/media/t5qjseih/blog-image-2.png?width=800&height=600&v=1d8741f3ba559d0)
Terese is a 64-year-old retired teacher who has a 12 year history of type 2 diabetes. She also has hypertension...
![Diabetes in General Practice](/media/1962/blog-image-1.png?width=800&height=600&v=1d75922bcdfe970)
It's one thing for a medication to demonstrate an effect in the narrowly selected, hermetically sealed and artificially monitored setting of a clinical trial.
![Cardiovascular outcome data in type 2 diabetes, does it really matter to me and my patients?](/media/1585/1920.jpg?width=800&height=600&v=1d75922b6f4b6d0)
So, we’ve heard about all this recent “exciting” cardiovascular outcome data in type 2 diabetes, but is there a real tangible benefit to our own patients outside of a clinical trial setting? How should we be incorporating it into our own clinical practice?
![Mental Health and Diabetes](/media/1557/diabetes-distress-blog-post-image.png?width=800&height=600&v=1d75922b5eda710)
The emotional health of people living with diabetes has been receiving greater attention as we become increasingly aware of the often-unrecognised psychological distress experienced by the approximately 1.2 million people in Australia living with diabetes.